Streetbeat News

MDAI

Spectral AI, Inc.

https://www.spectral-ai.com

Industry

Medical - Devices

Spectral AI, Inc. operates as an artificial intelligence (AI) company. The company focuses on medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView, a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. The company is based in Dallas, Texas.

Open

1.43

Mkt cap

21M

Volume

1.6M

High

1.44

P/E Ratio

-1.79

52-wk high

3.72

Low

1.03

Div yield

N/A

52-wk low

0.82

Spectral AI, Inc. (NASDAQ:MDAI) has completed a proof-of-concept module for its wound measurement technology, which calculates the total body surface area of burns. This technology, integrated into the DeepView® System, aims to improve the speed and accuracy of burn size estimation, crucial for acute burn management.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:13 pm

Spectral AI has achieved 25% patient enrollment in its US Burn Pivotal Study and has added two new clinical trial sites. This progress is significant for the company's research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:17 pm

Spectral AI plans to submit a De Novo request for its DeepView AI-Burn device to be classified as a Class II medical device by Q2 2025.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 12:05 pm

Spectral AI has received an $850K award from the Medical Technology Enterprise Consortium to further develop its AI-driven DeepView SnapShot M for assessing battlefield burn wounds. This brings its total non-dilutive government funding to over $7 million.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:24 pm

Spectral AI has completed enrollment at US burn centers for its US Burn Pivotal Study, marking a significant milestone in its research efforts.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:05 pm

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Spectral AI (NASDAQ:MDAI) and maintained a price target of $3.5.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:12 am

Spectral AI (NASDAQ:MDAI) reported Q2 2024 GAAP EPS of $(0.16), missing the $(0.15) estimate, but achieved sales of $7.478M, beating the $6.433M estimate. Sales increased by 75.91% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:03 pm

Northland Capital Markets has initiated coverage on Spectral AI (NASDAQ:MDAI) with an Outperform rating and a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:48 am

Spectral AI, Inc. (NASDAQ:MDAI) announced progress in developing the DeepView SnapShot M, a handheld AI-driven diagnostic tool for battlefield burn assessment.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:23 pm

Spectral AI, Inc. (NASDAQ:MDAI) announced a 30% increase in its patent portfolio, now holding 26 granted patents and 38 pending applications. This expansion strengthens the company's proprietary AI-driven DeepView System for wound assessment.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 12:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.